Cleveland BioLabs and Incuron Announce Updates on Clinical Progress With Curaxin CBL0137
January 06, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Jan 6, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced updates on...
Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
November 13, 2014 10:21 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Nov 13, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the...
Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
November 05, 2014 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Nov 5, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2014.
...
Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
October 28, 2014 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Oct 28, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2014, it will report its financial results for the third quarter ended...
Cleveland BioLabs Announces Approval to Start Phase 1 Study for Hematopoietic Stem Cell Mobilizer CBLB612 in Russian Federation
September 15, 2014 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 15, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced approval from the Ministry of Health of the Russian Federation to start a Phase 1 clinical trial...
Cleveland BioLabs and Sabby Announce Resolution of Litigation
September 08, 2014 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 8, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (collectively,...
Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
September 03, 2014 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 3, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed...
Cleveland BioLabs to Report Outcome of July FDA Meeting and Host Conference Call on September 3
September 02, 2014 16:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 2, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on September 3, 2014, it will report the outcome of the Company's July meeting with the U.S....
Cleveland BioLabs to Present at Rodman & Renshaw 16th Annual Global Investment Conference
September 02, 2014 09:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Sep 2, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment...
Cleveland BioLabs Reports Second Quarter 2014 Financial Results and Development Progress
August 07, 2014 07:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Aug 7, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2014.
...